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Abstract
Glioblastoma multiforme (GBM) is a lethal and nearly incurable disease. The C6 rat model of
GBM shares several similarities to human GBM and longitudinal imaging may allow tumour
features to be studied. In this thesis, a multimodality imaging framework, consisting of
bioluminescence imaging (BLI) and multiparametric magnetic resonance imaging (mpMRI),
was applied to the C6 rat model to characterize the growth of orthotopic tumours. BLI signal,
a measure of cell viability, tended to increase and then decrease in most of animals, whereas
tumour volume (from MRI) continually increased. Cellular viability and tumour volume did
not correlate across all days, highlighting the value of using complementary imaging
modalities. Apparent diffusion coefficient maps and immunohistochemistry suggests that
decreases in BLI signal are, in part, due to decreased tumour cellularity (i.e. necrosis). This is
the first use of BLI and mpMRI to characterize this model, and highlights the inter-subject
variability in tumour growth.
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General Introduction
1.1 Cancer and Brain Cancer (Glioma)
Cancer is the leading cause of death in Canada and is responsible for approximately 30%
of all deaths. It is estimated that 1 in 2 Canadians will develop some form of cancer in their
lifetime, and an estimated 1 in 123 Canadians will develop brain cancer (1). Glioma is the
most common form of malignant primary brain tumours and arises de novo from glial cells
in the brain (2). Unfortunately, glioma is the leading cause of cancer-related death in
children, adolescents, and young adults, being responsible for approximately 26% of
mortality among cancer patients (1).
Gliomas are classified based on morphological appearance and World Health Organization
(WHO) grades. Since gliomas do not necessarily resemble the glial cells they originated
from, they are categorized based on morphological appearance. Generally, gliomas may
resemble astrocytes, oligodendrocytes, or ependymal cells and are thus referred to as
astrocytomas, oligodendrogliomas, or ependymomas, respectively (3). In addition, the
WHO grades glioma into four groups based on histopathological features and malignancy
(4). Grade I gliomas, which are the least malignant, are lesions with minimal proliferative
potential and can be cured through surgical resection alone. Grade II gliomas are infiltrative
neoplasms that frequently recur despite the low proliferative potential and have the
potential to progress to higher malignancy grades. Tumours are categorized as grade III
when lesions have histological evidence of nuclear atypia and increased mitotic activity.
Grade IV tumours, specifically glioblastoma multiforme (GBM), are highly aggressive,
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malignant, invasive, proliferative and tend to develop necrotic foci, all of which are
associated with rapid disease evolution and extremely poor prognosis (4).

1.2 Glioblastoma Multiforme (GBM)
The most invasive and lethal primary brain tumour is a glioblastoma multiforme (GBM),
which accounts for approximately 50% of all glioma cases (2). GBM is considered as a
WHO grade IV astrocytoma and generally develops de novo, meaning these tumours can
develop spontaneously within the brain and does not arise from the migration of another
tumour found within the body (5). The 5-year relative survival rate, which is an estimated
measure for the probability of a patient surviving 5 years after diagnosis, for ages 20-44,
45-54 and above 55 is 14%, 4% and less than 1%, respectively (1). GBM is characterized
by its infiltrative growth, which makes differentiation between tumour tissue and normal
tissue nearly impossible in some cases, as well as its tendency to develop necrotic foci and
its ability to aggressively proliferate (5). There are two main necrotic formations described
by Urbanska et al.; one is large areas of necrosis near the centre of the tumour due to the
lack of blood supply and the second is smaller irregularly shaped necrotic areas throughout
the tumour. As the name suggests, GBM may contain heterogenous cellular features and
anaplastic cells, which can contribute to its severity and resistance to conventional therapy
(6). Despite aggressive treatment regimens, as described more extensively below, the
median survival time for patients after diagnosis of GBM is 12-15 months (4).
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1.2.1

Treatment of GBM

The standard treatment of GBM consists of complete surgical resection when possible,
followed by radiotherapy and temozolomide chemotherapy (7). However, this treatment
regimen almost always fails, in part due to the aggressive and infiltrative nature of this
disease (8). In addition, maximal surgical resection is not always possible due to the
inability to distinguish tumour from normal tissue, or the tumour’s location near essential
brain regions, and as a result, surgical resection may be inefficient (9). In addition,
chemotherapeutic efficacy may be further reduced due to the blood-brain barrier or regions
of poor vasculature within the tumour (10).
With the lack of effective treatment regimens available for patients, novel therapies have
been investigated such as; anti-angiogenic gene therapy to combat the rapid vascularization
of GBM (11), immunotherapy to increase survivorship (12), and hormone therapy to inhibit
GBM growth and to induce apoptotic pathways (13). The ability to image, monitor and
evaluate the tumour during treatment plays a key role in better assessing, understanding
and treating this disease.

1.3 Clinical Imaging of GBM
The ability to non-invasively measure and evaluate tumour progression will aid in the
diagnosis and control of GBM because the ability to detect these tumours sooner can
improve patient survivorship by beginning treatment before the tumour becomes too large
and infiltrative. In addition, evaluation of tumour response to therapy will aid in the
treatment of this disease because ineffective treatments may be identified sooner and

4

salvage treatment can begin, maximizing patient survivorship. The standard imaging
techniques used to diagnose and monitor patients with brain tumours are X-ray computed
tomography (CT), otherwise known as a computerized axial tomography scan, and
magnetic resonance imaging (MRI). CT scans are the standard for patients that are
ineligible for MRI, e.g. patients with pacemakers (14-16). MRI provides high-resolution
imaging with excellent soft tissue contrast, and unlike CT, does not require the use of
ionizing radiation. The availability of different pulse sequences to yield varying
endogenous contrast, in addition to the use of exogenous contrast agents, increases the
effectiveness of MRI to diagnose GBM, as well as obtain information about various
anatomical and functional characteristics within a GBM (16). For example, standard
anatomical imaging includes 2D or 3D pre-contrast T1- and T2-weighted, fluid-attenuated
inversion recovery (FLAIR), and post-gadolinium-diethylenetriaminepentacetate (GdDTPA) T1-weighted images. Several other imaging modalities or techniques have been
used to evaluate biological, functional and molecular features of GBM such as magnetic
resonance spectroscopy (17), blood oxygen level-dependent MRI (18), diffusion weighted
MRI (19), and perfusion MRI (20). In addition to MRI and CT, nuclear medicine
techniques such as positron emission tomography (PET)(21), and single-photon emission
computed tomography (SPECT)(22, 23) have also been used to monitor and evaluate GBM
progression.

1.3.1

MRI Diagnosis and Monitoring of GBM

MRI plays a key role in the diagnosis and treatment assessment of GBM. Patients will
undergo neurological exams and initial diagnostic imaging sessions if GBM is suspected.
Once GBM is confirmed by the neurologist, a biopsy, through surgical resection or fine
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needle aspiration, is performed to obtain tissue for pathological diagnosis (24, 25). Once
the tumour has been assessed, graded, and therapy has been planned, the patient will
undergo several additional MR imaging sessions. MRI serves as the standard to monitor
and evaluate tumour response to therapy over a period of weeks. MRI also provides
important information during treatment planning, e.g. planning the maximum safe margin
for surgical resection.

1.3.2

The Macdonald Criteria

The former standard for evaluating tumour progression and response was established by
the Macdonald criteria. These criteria are predominantly dependent on anatomical changes,
which may be changes in tumour enhancement on consecutive post-Gd T1-weighted MRI
scans obtained at least one month apart.
The tumour is assessed for changes based on the size of the largest cross-sectional area of
the enhancing tumour on post-Gd T1-weighted MRI. The size of the enhancing tumour is
measured by taking the product of two perpendicular maximal diameters on a twodimensional post-Gd T1-weighted MR image (26). In addition, the Macdonald criteria also
include neurological assessments and changes in steroid use when assessing treatment
response. Treatment response can be categorized into four groups: complete response,
partial response, progressive disease and stable disease.
Complete response occurs when there is a disappearance of enhancing tumour on
consecutive post-Gd T1-weighted MRI at least one month apart and patient neurological
function and behaviour improves without the use of steroids. Partial response occurs if
there is a greater than 50% reduction, relative to baseline, in enhancing tumour size over
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consecutive post-Gd T1-weighted MRI scans at least one month apart, with no new lesions.
Neurological behaviour must be clinically stable or improved and the patient must be on a
stable or reduced dose of steroids. Progressive disease occurs if the size of enhancing
tumour increases by more than 25% on consecutive post-Gd T1-weighted MRI scans at
least one month apart, with the appearance of new lesions or clinical deterioration. Stable
disease occurs if the patient does not meet the required changes in enhancing tumour size,
neurological function or steroid use. Thus, the patient cannot be categorized as complete
response, partial response or progressive disease, i.e., every other remaining situation (16,
26, 27).
The Macdonald criteria have proven to be extremely useful in the clinical assessment of
glioma response to therapy. However, there are several limitations including the difficulty
to measure irregularly-shaped GBMs and enhancing lesions in the cystic or surgical cavity
(because the cavity itself may be included in the measurement of tumour size),
interobserver variability and lack of criteria for measuring non-enhancing components of
the tumour on post-Gd T1-weighted MR images and multifocal tumours (28). One severe
limitation associated with the Macdonald criteria is that contrast enhancement from GdDTPA is non-specific and primarily reflects the passage of contrast agent across a disrupted
blood-brain barrier. This enhancement may be influenced by other factors such as dose of
steroids, anti-angiogenic therapy, inflammation, ischemia, post-surgical change, and
radiation necrosis. Thus, these tumours may be subject to a phenomenon known as
pseudoprogression or pseudoresponse. Pseudoprogression refers to a temporary increase
in enhancement size in post-Gd T1-weighted MRI post-treatment when compared to
baseline MR images. This may cause the misdiagnosis of the tumour to be categorized as
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progressive disease, when in fact these changes are transient and not reflective of the true
nature and size of the tumour. These changes may be associated with an increased
permeability to contrast agent following radiotherapy and chemotherapy and may
ultimately lead to premature discontinuation of adjuvant therapy. On the contrary,
pseudoresponse refers to a temporary decrease in enhancement size in post-Gd T1-weighted
MR

images

post-treatment

when

compared

to

baseline

MR

images.

Like

pseudoprogression, these changes are transient and may cause the incorrect clinical
assessment of a non-responding tumour, ultimately leading to several weeks of ineffective
therapy (28).
A newer method of treatment assessment, which has largely superseded the Macdonald
criteria, is referred to as the Response Assessment in Neuro-Oncology (RANO) criteria
and has been developed to address the drawbacks and limitations associated with the
Macdonald criteria by introducing several additional measurements encompassing a wider
range of factors to increase clinical assessment reliability (15, 20).

1.3.3

Response Assessment in Neuro-Oncology (RANO) Criteria

The current gold standard for clinically assessing GBM response to treatment is the RANO
criteria. It largely builds upon the foundation of the Macdonald criteria, while adding
additional measurements and standardizing imaging definitions. The RANO criteria
utilizes T2, FLAIR, and post-Gd T1 MR images to accurately and reliably assess treatment
response when compared to the Macdonald criteria. T2-weighted MRI provides contrast of
the tumour without the use of contrast agent, while FLAIR MRI provides similar contrast
to T2-weighted MRI but suppresses signal from fluids such as the cerebral spinal fluid
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(CSF). Post-Gd T1-weighted MRI provides signal enhancement of tumour tissue but
requires the delivery of Gd-DTPA to tumour tissue. The RANO criteria incorporate
measurements of multifocal tumours and enhancing and non-enhancing lesions using the
product of the maximal cross-sectional diameter as used in the Macdonald criteria. Where
enhancing and non-enhancing lesions refer to lesions seen on post-Gd T1-weighted and
FLAIR/T2-weighted MRI, respectively. In addition, the RANO criteria make an important
distinction between measurable and non-measurable disease detected using contrast
enhancement. Where measurable disease refers to tumours with a minimal size both in and
out of plane, have contrast enhancement on post-Gd T1-weighted MRI and do not include
the cavity, cyst or necrosis. Non-measurable disease refers to lesions that are too small, do
not enhance (in other words seen only in T2/FLAIR MRI) or have poorly defined margins.
The RANO criteria assert that a lesion is considered measurable when there is bidimensional contrast enhancement with clear tumour margins in post-Gd T1-weighted MRI
with a minimal size requirement of 10 mm if the slice thickness is less than 5 mm and two
times the slice thickness if the slice thickness of the image is larger than 5 mm. It also
specifically states that any cystic or surgical cavity should not be measured unless there is
a measurable lesion at least 10 mm in diameter. Non-measurable lesions generally do not
meet the requirements above. They are defined as unidimensional lesions, tumour masses
without a clear defined margin or lesions not greater than 10 mm in the maximal
perpendicular diameter.
Patients without measurable lesions cannot be categorized as responders to treatment and
can only achieve stable disease. The RANO criteria consider multiple contrast-enhancing
lesions, and a minimum of two to five lesions will be measured to determine the size of the
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tumour, which will be used to assess treatment response. However, the RANO criteria
emphasize reproducibility and accuracy of measurements; therefore, multifocal lesions
with large measurement uncertainties may be omitted and the next best lesion may be
measured.
The RANO criteria also address the large issue of pseudoprogression during the first 12
weeks of chemoradiotherapy. Thus, progression is only defined when there is tumour
enhancement outside the radiation field in post-Gd T1-weighted MRI, or if there is
histological evidence of large tumour areas. Beyond 12 weeks, disease progression is
deemed to occur when; 1) there are new contrast-enhancing lesions outside of the radiation
field regardless of steroid use, 2) if there is a greater than 25% increase in tumour size from
the first post-radiotherapy scan to subsequent scans 12 weeks later with increased or
maintained steroid use, 3) clinical deterioration not associated with therapy occurs, and 4)
there is a significant increase in T2-weighted or FLAIR non-enhancing lesions in patients
undergoing antiangiogenic therapy.
Within this assessment framework, the RANO criteria categorize treatment response into
four groups; complete response, partial response, stable disease or progression. Complete
response occurs when there is a disappearance of all enhancing and non-measurable disease
over a period of at least 4 weeks. Non-enhancing lesions evident after T2-weighted or
FLAIR MRI are those that have stabilized or reduced in size and the use of steroids are
stable or reduced from baseline. Partial response is defined by a greater-than-50% size
reduction in all measurable enhancing lesions, no progression of non-measurable disease,
no new lesions, stable or improved lesions on T2 or FLAIR MRI, and stable or lower steroid
usage between scans at least four weeks apart. Stable disease is defined by tumours that do
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not meet all the criteria for the other treatment response groups, but where there are no new
T2 or FLAIR lesions on the same or lower steroid dose when comparing the baseline scan
to the post-treatment scan. Progression occurs if any of the following occur; 1) the sum of
perpendicular diameters of enhancing lesions increase by more than 25% on stable or
higher steroid doses, 2) there is a significant increase in T2 or FLAIR non-enhancing
lesions, 3) new lesions appear, or there is clear progression of non-measurable lesions or
clear-clinical deterioration of the patient’s health (27, 28).
The Macdonald criteria predominantly relied on changes in tumour size based on post-Gd
T1-weighted MRI, patient neurological behavior and corticosteroid use, to assess treatment
response without considering other imaging contrast techniques, irregular shaped and
multifocal tumours. On the other hand, the RANO criteria places emphasis on measuring
lesions on multiple imaging contrast techniques such as, FLAIR, T2, post-Gd T1-weighted
MRI. The RANO criteria applies stricter guidelines to measure tumours and categorize a
patient as responsive or progressive, such as including chemoradiotherapy timing,
corticosteroid use, type of treatment applied, measuring multifocal tumours, measuring
non-enhancing lesions and considering lesions as measurable or non-measurable based on
anatomical features. The RANO criteria are continually evolving to consider modern
advances in neuroimaging and discoveries related to GBM biology. Although the RANO
criteria have updated and improved the foundations set by the Macdonald criteria,
significant limitations are still apparent such as the lack of implementation of volumetric
information and the minimum time requirement between scans required for assessing
treatment response.
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1.4 Preclinical GBM Models
Preclinical animal models are extremely useful to allow researchers to better understand
tumour biology and disease progression, and to test novel therapeutics prior to their
translation into patients. Animal models, such as rodents, are important tools in
experiments because they are easy to handle, have a short life span, and develop a central
nervous system similar to that of humans. Novel imaging techniques may be developed to
address clinically-relevant issues such as the lack of accurate and reliable metrics to
measure tumour response to therapy. For instance, imaging techniques such as anatomical
MRI and diffusion-weighted imaging (DWI) have been applied to assess the effects of
novel therapies in these models (19, 29).
Various animal models have been developed that recapitulate features seen in human GBM
such as; 1) a similar genetic background, 2) intratumoral heterogeneity that includes
genetic, epigenetic or phenotypic changes, 3) similar microenvironmental features such as
the presence of the blood-brain barrier (BBB), cellular interactions, immunological
responses, and 4) stability and reproducibility (30). There are currently many murine GBM
cell lines used to mimic human GBM once they’ve been implanted into the brains or bodies
of mice, such as the U251, U87, and GL261 cell lines. Each species-specific model has its
own particular limitations and advantages, and each glioma model provides varying
similarities to human GBM but may have several other applications (31). For example, the
U251 glioma model shares several histological and immunohistochemically features of
human GBM, genetic alterations and imaging features, such as necrosis. The U87 model
has several dissimilarities to the U251 and human GBM, but proves an excellent model to
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assess angiogenesis and anti-angiogenesis therapy (32). The previous two models rely on
immune incompetent mice, while the GL261 syngeneic model does not. Thus, GL261
orthotopic homografts may experience an immunological response that is typically found
in patients, and thus tumour progression may closely mimic human GBM progression (31).
This is a particularly strong model for evaluating immune-based therapies (31). In addition,
patient-derived xenograft (PDX) GBM models is an attractive alternative. These tumours
are obtained from patients and are directly implanted into animals and are based on the
assumption that these models faithfully resemble the original tumours.
However, detailed imaging of the mouse brain may be limited due to the inherently small
size of the brain. The ability to visualize intratumoural features may be limited due to
limited spatial resolution and signal-to-noise ratio (SNR) of some imaging modalities (33).
To address this limitation, state-of-the-art MRI hardware is required specifically for small
animal imaging, which may be costly and available at a few imaging centres all over the
world. Thus, an alternative animal host, such as rats, may be used to study GBM.
Rat models using rat glioblastoma cell lines such as the C6, 9L, CNS-1 or F98 have proven
to be useful to probe tumour biology and progression in the brain (31, 34). The 9L rat
glioblastoma model has been extensively used to study chemotherapy or radiotherapy
regimens (34), and has served as a useful model to better understanding human GBM.
However, the 9L is considered a gliosarcoma, which is a subset of grade IV gliomas (34).
Therefore, this model may not represent human GBM reliably and accurately, and one of
its greatest limitations is that it does not show the diffuse infiltrative growth found in human
GBM (31). The CNS-1 model is a relatively newer relative to the C6 and 9L rat models
and thus lacks extensive literature reporting the genetics and biology of the model.
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However, it shares several histological markers and growth patterns with human GBM and
serves as an excellent model to understand human GBM (31). The F98 glioma model shares
several characteristics, such as increased expression of cancer genes and/or proteins, to
human GBM and C6 cells. This model expresses highly invasive growth patterns with
fairly low immunogenicity, making it an attractive model to evaluate therapeutic agents
and to better study the mechanisms underlying glioma resistance to immunotherapy. The
F98 model has also been genetically engineered to express the BLI reporter gene,
luciferase, to monitor tumour size (34). The C6 model, which was used in this project, is
described more fully in the next section.

1.4.1

C6 GBM Rat Model

The C6 cell line was first developed by Benda et al. (35) and Schimdek et al. (36) in the
1960’s by repetitively administering a carcinogen known as N-Nitroso-N-methylurea over
a period of 8 months into outbred Wistar rats. The C6 GBM rat model was first described
by Auer et al. (37), and it is an intracranial brain tumour model used to study GBM
experimentally. The model was developed by injecting 1 to 5 x105 C6 cells into the brains
of rats. These tumours developed similar morphologically features to human GBM and
became a popular animal model to study the progression and treatment of human GBM.
Since its development, the pathological, molecular, and genomic characteristics of the C6
model have been extensively characterized (8, 37-40). This model shares several
histopathological and specific tumour markers with human GBM such as diffuse
infiltrative growth patterns (31), nuclear pleomorphism, high mitotic activity, regions of
necrosis within the tumour, hemorrhage, and parenchymal invasion (40). Recent molecular
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characterization of this cell line has shown several changes in gene expression reported in
human tumours (38).
The C6 cell line is reported to have mutations in the p16/Cdkn2a/Ink4a locus (39), which
is commonly associated with tumour suppression and often mutated in human GBM.
However, the C6 has a wildtype tumour suppressor gene, p53, (41) unlike human GBM.
When compared to astrocytes, the C6 cell line has increased gene expression of plateletderived growth factor-beta (PDGFβ), insulin-like growth factor 1 (IGF-1), epidermal
growth factor receptor (EGFR), and human epidermal growth factor receptor 3 (Her3)
genes, which are commonly overexpressed in human gliomas (34). C6 cells have increased
activity of the Ras pathway also seen in human GBM and contrary to what has been
reported for human GBM, C6 cells have an increased expression of retinoblastoma protein
(34).
The study of the C6 rat model has contributed to the clinical understanding of GBM and
its treatment, which includes the extent of tumour progression, the potential for
spontaneous regression, the patterns of cell infiltration and neoangiogenesis (42). This
model has been extensively used in various experimental neuro-oncology studies using
novel treatment modalities such as anti-angiogenic therapy (43), cytotoxic gene therapy
(44), and treatment with toxins (45). In addition, this model has found an extensive use to
evaluate the efficacy of immunotherapy because the C6 cell line was found to be
immunogenic in all rats including the Wistar rat, which the model was derived (34).
Evaluating immunotherapy in an immune component animal capable of exhibiting an
immune response is beneficial because it closely mimics the biology and immune response
seen in of human GBM.
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Advances in modern non-invasive neuroimaging techniques and modalities has provided
an opportunity to better understand and study GBM. The imaging of this model will be
further discussed in the next section.

1.5 Imaging of the C6 GBM Rat Model
The ability to non-invasively image GBMs in vivo has provided a great deal of information
regarding the formation and development of such tumours. Advances in modern
neuroimaging techniques have improved the characterization of physiology and
metabolism of GBM which may lead to improved clinical assessments and outcomes (46).
The identification and pursuit of potential biomarkers for imaging in GBM may provide
new opportunities to better treat and understand this disease.
Many imaging modalities and techniques have been applied to the C6 rat model and
reported in the literature. Some examples include; standard anatomical imaging used in
patients such as pre-contrast T1-weighted and T2-weighted MRI, FLAIR MRI, post-Gd T1weighted MRI (42), and CT (47). In addition, relatively newer MR techniques have been
explored including DWI (48), diffusion tensor imaging (DTI)(49), perfusion-weighted
imaging (PWI)(50), proton (1H) magnetic resonance spectroscopy (MRS)(51), and
hyperpolarized (HP) 13C magnetic resonance spectroscopic imaging (MRSI)(52). The C6
rodent model has also been imaged using various PET tracers such as 18F-fluorodeoxy-Dglucose (FDG)(53) to probe glucose metabolism within the tumour,
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F-fluoro-ethyl-L-

tyrosine (FET)(54) to delineate tumour tissue from healthy tissue and to aid in the
identification of malignant tissue,
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F-fluoromisonidazole (FMISO)(55) which identifies

regions of hypoxia, perfusion CT (56), and 123I-iodo-L-α-methyltyrosine SPECT (57).
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Preclinical models are amenable for the use of imaging modalities because novel imaging
modalities or techniques may be used and can offer additional advantages at a lower cost.
For instance, BLI, discussed more fully below, can provide direct measures of relative
cellular viability over time, which is a measurement of live cells based on enzymatic
activity and light production. Literature description of the use of BLI with the C6 cell line
is relatively sparse. For example, Yeom et al. visualized hypoxia-inducible-factor-1 in
xenograft mice models using BLI (58). Jang et al. explored the use of BLI to monitor the
therapeutic efficacy of a novel treatment in a C6 mouse model (59). To date, Xi et al. has
been the only group to apply BLI to a C6 rat model. They used BLI to longitudinally
monitor the efficacy of two novel therapies in a brainstem xenograft C6 rat model (60, 61).
Novel therapies may be evaluated using a combination of these imaging modalities to
provide significantly more information than the use of a single imaging technique.

1.6 MRI and Multiparametric MRI (mpMRI) in the C6 Rat
GBM Model
Magnetic resonance imaging (MRI) is a non-invasive in vivo imaging modality capable of
obtaining both anatomical and functional information within the body. MRI involves the
interaction of a nucleus (e.g. 1H) in a molecule within tissue with an applied external
magnetic field. MRI utilizes large static magnetic fields from superconductive magnets,
rapidly manipulated magnetic field gradients from resistive magnets, and radiofrequency
(RF) excitation and reception to generate images based on intrinsic physical properties of
the nuclei. These include nuclear spin, gyromagnetic ratio, abundance, spin-spin (T2) and
spin-lattice (T1) relaxation values.
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The usual nuclei imaged in conventional MRI is the ubiquitous proton (1H) associated with
the water molecule. Intrinsic properties such as ½-nuclear spin, large gyromagnetic ratio,
and high concentration in tissue make it the most useful nucleus for in vivo MRI. The
nuclear spin angular momentum, colloquially known as “spin”, is a quantum mechanical
property. Nuclei can possess only integer or half-integer spin and spin-1/2 nuclei are the
most useful for MRI due to the manner in which they interact with electric and magnetic
fields they experience within their environment. These interactions govern properties such
as spin-lattice and spin-spin relaxation. The strength of interaction of a nucleus with an
applied magnetic field is proportional to its nuclear magnetic dipole moment. The
gyromagnetic ratio is the ratio of a particle’s magnetic dipole moment to its spin angular
momentum. Therefore, a nucleus with a larger magnetic moment (and thus a larger
gyromagnetic ratio) will interact more strongly with an external field and produce more
signal for MRI. MR anatomical imaging is possible due to these favourable intrinsic
properties of protons and their large abundance (in the form of water) within the body. This
facilitates high-resolution three-dimensional imaging with excellent soft tissue contrast.
A typical MRI instrument consists of three distinct electromagnetic systems; the main
magnetic field, the gradient fields, and the RF transmit/receive system. A system of
superconducting magnet windings creates the strong main magnetic environment (B0)
required for magnetization of the protons within water molecules. In the absence of an
external magnetic field, the magnetic dipole moments of nuclei are randomly oriented.
However, when protons are exposed to an external magnetic field, they begin to precess
around the field direction. For an ensemble of magnetic dipoles, the angles of the
precessional cone are nearly randomly distributed with respect to the magnetic field
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direction but are slightly skewed in the direction of the field. This produces a weak net
“magnetization” along the magnetic field direction. It is this “longitudinal” magnetization,
that is the source of the signal for MRI. The amount of magnetization depends on the
magnetic field strength, the gyromagnetic ratio of the nucleus and its abundance in the
body.
The gradient coil system consists of layers of resistive magnet windings wound on a
cylindrical form located inside the superconducting magnetic field, B0. These gradient
magnets superimpose a linear spatial change in the homogenous main magnetic field in
three orthogonal directions, Gx, Gy and Gz. These linear gradients are independently
manipulated with great speed to alter the frequency and phase of the precessing nuclei
within the main magnetic field. Systematic control of this motion is known as frequency
and phase encoding, which is used to “encode” the MRI signal with spatial information so
that three-dimensional imaging data can be acquired.
The RF coil is located within the gradient structure. Its purpose is to transmit the RF energy
(B1) required to excite the magnetization of the protons of water molecules present in tissue
and to detect its subsequent electromagnetic signal, which is used to produce an image.
The B1 magnetic field is oriented orthogonally to the main magnetic field and oscillates (or
rotates) at the nuclear precession frequency. This is known as the Larmor frequency, which
is equal to the product of the nuclear gyromagnetic ratio multiplied by the magnetic field
strength. The B1 field causes a portion of the longitudinal magnetization of the protons to
be excited (or tipped) into the plane orthogonal (i.e. transverse) to the main magnetic field.
The resulting “transverse magnetization” precesses around B0 at the Larmor frequency, as
its amplitude decays with an exponential time constant, T2, known as the spin-spin
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relaxation constant. Spin-spin relaxation is an intrinsic tissue property. For example, the T2
relaxation times of CSF and fat at the clinical field strength of 3 Tesla (T) are approximately
2000 ms and 70 ms, respectively (62). This difference in spin-spin relaxation time for
various tissues can be exploited to produce image contrast for MRI known as T2-weighted
imaging and can be used to differentiate morphology based on tissue type. In addition,
during the loss of transverse magnetization, the longitudinal magnetization recovers
asymptotically to its equilibrium along B0. This is known as spin-lattice relaxation and is
characterized by the exponential time constant, T1. As with T2 relaxation times, T1
relaxation times are tissue specific. For example, the T1 relaxation times for CSF and fat at
3 T are 4000 ms and 250 ms, respectively (62). Again, this intrinsic magnetic property of
the protons in tissues can also be used to produce an endogenous image contrast known as
T1-weighted contrast. In addition to T1- and T2-weighted contrast other imaging contrasts
can be generated such as proton density contrast and diffusion-weighted images.
Extrinsic parameters such as repetition time (TR) and echo time (TE) influence the
manipulation of the proton magnetization during image acquisition, which in turn affects
imaging contrast and SNR. The repetition time refers to the time between RF excitation
pulses. The echo time refers to the time between the initial RF pulse excitation and the
centre of the signal echo used to refocus (or recycle) the transverse magnetization. These
are key timing parameters for systematic application of the gradient and RF fields by the
MRI pulse sequence and they control image contrast. The most basic sequences include
free induction decay (FID), gradient recalled echo (GRE) and spin echo (SE) sequences.
The pulse sequence and timing parameters are chosen to obtain tissue- or disease-specific
contrast for diagnosis. Generally, shorter TE and TR values are associated with T1-
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weighted imaging while longer TE and TR values are associated with T2-weighted imaging.
T2-weighted imaging is more sensitive to pathologies compared to T1-weighted imaging
because tissues associated with disease often have higher water content than normal, and
thus have a longer T2 and appear brighter (63). This is the case for GBM. However, other
tissue contrasts can be obtained by adjusting TE and TR to exploit intrinsic differences in
T2 and T1. For example, rapid successive RF pulses (short TR), will prevent tissues with a
long T1 from recovering back to equilibrium, whereas tissue with shorter T1 values still
achieve appreciable relaxation. These parameter timings produce T1-weighted image
contrast, preferentially highlighting tissues with faster spin-lattice relaxation or those
enhanced by the presence of exogenous T1-contrast agents. T1-weighted imaging is useful
for differentiation of white and gray matter in neuro-imaging (64).
The combination of the intrinsic physical properties of hydrogen nuclei and their large
concentration in human tissue bound as water make it possible to non-invasively image
their in vivo distribution with excellent tissue contrast, spatial resolution and SNR. In
addition to exploiting intrinsic tissue properties with a range of MR imaging contrasts,
healthy and diseased tissues can be further distinguished by the introduction of exogenous
contrast agents. Paramagnetic contrast agents, such as Gd-DTPA have been used in the
imaging of brain tumours to highlight morphological features undetectable with noncontrast enhanced imaging.
The use of paramagnetic contrast agents, which enhance the spin-lattice relaxation of
neighbouring tissue, can increase the contrast between healthy tissue and tumour.
However, there are several limitations associated with Gd-DTPA. Patients with impaired
renal function cannot fully clear Gd-DTPA, which results in the accumulation of contrast
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agent in tissue and could potentially lead to nephrogenic systemic fibrosis. Gd-DTPA does
not readily penetrate the blood-brain-barrier (BBB) and, therefore, will only provide
contrast enhancement of brain tissue if the BBB is disturbed. Lastly, Gd-DTPA lacks
specificity as a contrast agent and does not directly target tumours. Gd-DTPA provides
contrast enhancement in regions where the contrast agent can extravasate from the
vasculature into the surrounding interstitial space in the event of an impaired BBB or
blood-tumour barrier (BTB). Therefore, invasive therapies such as maximal surgical
resection or anti-angiogenic treatment can falsely produce regions of tumour enhancement
or lack of enhancement and ultimately may adversely affect the evaluation of treatment
response. Given the limitations associated with anatomical imaging and detecting
morphological changes in GBM, more sensitive and specific methods for tumour imaging
are required to better diagnosis and treat this disease.
Diffusion and perfusion weighted MR imaging have been shown to be useful diagnostic
tools when used in addition to standard anatomical imaging. Additional metrics obtained
from DWI and PWI, such as tissue cellularity or blood perfusion, have been shown to be
beneficial when discriminating responding and non-responding patients undergoing
chemo- and radiotherapies (65). The ability to accurately assess tumour treatment response
will prevent non-responding patients from undergoing weeks of ineffective therapy and
will prevent responding patients from prematurely ending adjuvant therapy due to a
misdiagnosis. Important data such as cerebral blood flow and volume can be measured with
PWI, which is useful when determining blood delivery within the brain and specifically
within or around the tumour. This is especially important when assessing the potential
delivery of a chemotherapeutic to tumour tissue. In addition, PWI has been shown to be
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very useful when differentiating between high or low grade glioma, lesion type or to aid in
the identification of a primary or metastatic tumour (66).
The use of a panel of MRI imaging contrasts is known as multiparametric MRI (mpMRI).
Depending upon the disease, a specific set of imaging contrasts are chosen, which are
effective at discriminating a certain aspect of the pathology. For cancer, mpMRI provides
complementary imaging information for the oncologist to assess treatment response or to
understand tumour progression. The following section will outline the specific mpMRI
techniques used in this preclinical research study.

1.6.1

T1-, T2-, Post-Gd T1-weighted and Diffusion MRI

The main mpMRI imaging contrasts used in this thesis include T1- and T2-weighted, postGd T1-weighted and DWI. As explained previously, spin-lattice (T1) and spin-spin (T2)
relaxation are intrinsic tissue properties, which can be exploited to obtain contrast between
tissues to improve the appearance of morphological features inside the brain or to
differentiate between tumour and healthy tissue.
T2-weighted imaging emphasizes contrast based on water content within brain tissue. CSF
and water have longer T2 relaxation times relative to other brain tissue, therefore CSF and
tissues with high water concentration will appear bright on a T2-weighted image.
This imaging technique is used in the clinical assessment of GBM because the inherent
nature of tumour tissue creates hyperintense signals when compared to healthy tissue and
aids in the identification and differentiation of tumour and healthy tissue. Due to the
heterogenic cell composition of GBM and its irregular morphology, cells are coarsely
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packed, and as a result, the larger fluid-filled extracellular space around tumour cells
represents a larger volume fraction in tumours compared to healthy brain tissue (67). In
addition, rapidly dividing tumour cells may cause fluid buildup or edema (68). The
identification and differentiation of edema caused by GBM is important in the diagnosis
and treatment of the disease because the edema may be misidentified as tumour mass and
vice versa, amongst other factors. The presence of edema due to glioma may be
unfavourable to the patient because of the increased peritumoural invasion and increased
error in estimating tumour mass, which may have a large impact on the clinical planning
of GBM (69).
T1-weighted imaging, sensitive to the longitudinal relaxation of tissue, is another useful
endogenous imaging contrast. For example, CSF appears hypo-intense due to the long T1
times associated with free water, while fat appears as hyper-intense due to the more
efficient relaxation of protons in the large molecules associated with fatty lipids. T1weighted imaging is less sensitive to pathologies than T2-weighted imaging due to the lack
of tissue specific contrast enhancement related to disease. However, the use of
paramagnetic contrast agents can alter tissue-specific contrast and post-Gd T1-weighted
imaging can be used to identify and characterize brain lesions. Typically, pre-Gd T1weighted imaging is done to establish a baseline. This image is compared to a second postGd T1-weighted image to determine which regions show increased signal corresponding to
contrast agent delivery or accumulation. Since the BTB is much more permeable to GdDTPA than the BBB, perfused regions of tumours often show significant contrast
enhancement post-injection (50). Contrast-enhanced imaging is especially useful when
lesions are not detectable by T2-weighted imaging and may aid in differentiating edema
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from tumour mass and regions of necrosis (70). T1-weighted imaging is the main imaging
technique for assessing GBM response to treatment under the Macdonald criteria, but
limitations exist associated with use of Gd-DTPA, which have been discussed previously
(26, 27). Additional imaging techniques are often used as part of mpMRI to better identify
tumour mass and to improve the detection of tumours and their response to treatment (29).
Diffusion-weighted imaging is an MRI technique that has previously shown to help the
diagnosis and the evaluation of tumour treatment response (65). DWI measures the random
translational (Brownian) motion of water molecules which is influenced by tissue structural
integrity or cellularity (48, 71). The quantitative metric, known as the apparent diffusion
coefficient (ADC), obtained from DWI has been shown to be inversely proportional to
tissue cellularity (72, 73). Regional ADC measurement using DWI is a potential imaging
biomarker for the assessment of treatment response (74), and the identification of necrosis.
The combined use of these different mpMRI techniques has provided a range of metrics to
identify tumour lesions and tumour response to treatment. Each imaging technique can
provide complementary information related to the tumour environment and, in
combination, produce a more complete understanding of the biology of tumour
progression.

1.7 Bioluminescence Imaging
Complementary imaging modalities are required to address the limitations of mpMRI, such
as the inability to directly measure tumour cell viability and that anatomical changes are
slow to occur and detect, and one possible modality that can directly measure relative
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tumour cell viability is bioluminescence imaging (BLI)(75). BLI is a preclinical optical
molecular imaging modality that benefits from high sensitivity (e.g., single (76) to
thousands of cells in vivo could be detected (77)), low cost, extremely high SNR due to the
lack of intrinsic bioluminescence from tissue, the ability to image multiple animals within
minutes, the ability to detect changes in tumour cell viability within a short time frame, and
sufficient sensitivity to detect tumour cells immediately after implantation into an animal
(77, 78). BLI has a wide range of applications in cancer imaging, such as, but not limited
to, detection of metastatic formations throughout the mouse or rat body (76), evaluation of
novel therapies in xenografted prostate cancer in mice (79) and ovarian cancer in mice (80),
capacity to monitor the presence of genetically-modified bacteria and their role in
inhibiting tumourigenesis in the orthotopic C6 rat model (81), and capacity to monitor
effectiveness of gene therapy in a C6 glioma mouse model (59). However, BLI lacks the
ability to obtain 3D anatomical imaging using various contrast mechanisms seen in mpMRI
and is ultimately a preclinical imaging modality. Thus, the combined use of both BLI and
mpMRI can address the limitations associated with each individual modality while
benefiting from the advantages.
A requirement for BLI studies is that cell lines need to be genetically-engineered to express
a luciferase reporter. There are many luciferase reporters available to use in BLI such as
Firefly luciferase (FLuc) from Photinus pyralis (i.e., the North American firefly), the red
shifted Luciola Italica luciferase (Luc), or Renilla luciferase (RLuc) from Renilla
reniformis (i.e., the sea pansy). The most common reporter used is FLuc because it is the
most efficient bioluminescence system to date and most studied. FLuc yields the highest
light output efficiency in vivo and the standard FLuc emits green light which has minimal

26

light absorption from tissue. In addition, there is increased use of red-shifted luciferases
such as Luciola italica (Italian firefly) for deep tissue imaging because of the decreased
tissue light absorption (82). FLuc was first cloned in 1985 (78) and many years later, has
found use in many preclinical in vivo studies (83-85). Several glioma cell lines have been
genetically-engineered to express FLuc, for example Maguire et al. utilized a trimodal BLI
approach to image the effect of soluble tumour necrosis factor-related apoptosis-inducing
ligand on U87 cells implanted into the mouse brain (86). Sun et al. has used BLI to image
and assess angiogenesis during progression of a orthotopic GL26 murine model (87). Jost
et al. has utilized a BLI and MRI approach to image the progression of a Dihydrolipoamide
branched chain transacylase E2 (DBT) glioblastoma cell line in an orthotopic murine
model (85). Lenten et al. has imaged the effect of suicide gene therapy in a orthotopic
GL261 murine model (88).
For cells expressing Luc, bioluminescent light is produced by a catalytic reaction involving
Luc and its substrate D-Luciferin (D-Luc), as well as the cofactors adenosine triphosphate
(ATP), oxygen, and magnesium (Mg2+). Figure 1-1 represents the catalytic Luc reaction
which converts D-luciferin to oxyluciferin at the expenditure of ATP to adenosine
monophosphate (AMP).
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𝐿𝑢𝑐 + 𝐷𝐿𝑢𝑐𝑖𝑓𝑒𝑟𝑖𝑛 + 𝑂2 + 𝑀𝑔2+ + 𝐴𝑇𝑃
→
𝐿𝑢𝑐 + 𝑂𝑥𝑦𝑙𝑢𝑐𝑖𝑓𝑒𝑟𝑖𝑛 + 𝐶𝑂2 + 𝑀𝑔2+ + 𝐴𝑀𝑃 + 𝐿𝑖𝑔ℎ𝑡
Figure 1-1. Bioluminescence chemical reaction equation.
In the presence of all the necessary cofactors (ATP, O2 and Mg2+), the Luc enzyme can
catalyze D-Luc into Oxyluciferin. This produces light in the 620-nm region, which can
then be collected on a camera to produce BL images.
A benefit of BLI is the low background noise during the imaging because tissue does not
naturally express luciferases nor do they naturally luminesce. Only viable tumour cells will
produce light because only metabolically active tumour cells will be able to transcribe Luc,
as well as produce the ATP needed to generate luminescence. Typical BLI equipment
consists of a light-tight chamber and a cooled charge-coupled device (CCD) camera to
reduce thermal noise. The chamber prevents external light from entering and its blackened
interior surfaces prevents detection of scattered bioluminescent light from chamber walls.
The cooled CCD camera sensitively collects light emitted from the bioluminescent source.
The sensitivity of bioluminescence imaging largely relies on the depth of the luminescent
cells, as optical imaging modalities have limited depth of penetration within tissue due to
light scattering and tissue absorption. In addition, bioluminescence sensitivity is also
influenced by the technology of the CCD camera itself, the amount of substrate, and level
of luciferase activity per cell.
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A typical BLI experiment begins with anesthetizing the rodent and injecting D-Luc in one
of three substrate delivery methods; intraperitoneal, intravenous, or subcutaneous.
Intraperitoneal injections are the most common route of substrate delivery due to the
extended and high bioluminescence output profile, as imaging is typically done when light
output has peaked to reduce variability between animals. However, any variations in DLuc absorption can have an influence on bioluminescent signal, such as the injection of
substrate into the gut rather than the intraperitoneal space. Intravenous injections require
lower doses to achieve similar bioluminescence intensities but are quick to peak and clear
through the body. Subcutaneous injections can be used to avoid the shortcomings
associated with intraperitoneal injections but have a much longer lag time associated with
time to signal peak (89).
By combining two imaging modalities, mpMRI and BLI, that provide complementary
information, the limitations associated with each modality can be minimized while
obtaining a large range of useful, imaging metrics. BLI provides high SNR images,
sensitive cell specific information, a reliable measure of the relative number of viable
tumour cells over time and immediately after tumour implantation into an animal while
minimizing cost and time with the ability to image multiple animals within a short time
frame. However, BLI is limited to 2D preclinical imaging due to a lack of penetration depth
within tissue associated with light scattering and tissue absorption, which can reduce
sensitivity and limit spatial information within deeper layers of animal tissue. BLI is
dependent on substrate delivery for signal production, thus has similar limitations
associated with imaging modalities that rely on substrate delivery (e.g., PET/SPECT),
particularly lack of enhancement in ill-perfused regions. Whereas mpMRI is the gold
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standard for the diagnosis and assessment of GBM and its response to treatment with
various contrast mechanisms. However, mpMRI lacks the sensitivity and ability to directly
measure tumour cell viability.

1.8 Thesis Overview
Conventional MRI (FLAIR/T2/post-Gd T1) is a powerful imaging modality for the
diagnosis and assessment of tumour response to therapy. However, this imaging modality
is generally restricted to only providing anatomical information, which may be inaccurate
and changes may be slow to occur, ultimately affecting the planning and success of therapy.
Multiparametric MRI consists of a larger suite of imaging techniques, which include DWI
and PWI, capable of providing functional information alongside anatomy. These imaging
techniques have been shown to improve the diagnosis of GBM and assessment of its
response to therapy (90). Utilizing additional imaging metrics can provide information
which can aid to differentiate radiation necrosis from recurrent GBM, which is usually
indifferentiable in conventional post-Gd T1-weighted MRI. The ability to obtain more than
one piece of information of GBM will provide the clinician with a better understanding of
tumour behavior and can improve assessment and treatment of GBM. Although mpMRI
addresses and improves on the limitations of conventional MRI, there are no imaging
methods or techniques in mpMRI that can measure tumour cell viability. A complementary
imaging modality known as BLI may be best suited to address this limitation of mpMRI in
preclinical animal models of GBM as it provides a direct measurement of relative tumour
cell viability with high sensitivity and specificity.
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The purpose of my thesis was to develop a multimodality imaging framework using both
BLI and mpMRI to characterize the natural progression of orthotopic C6 glioblastoma
multiforme expressing red-shifted Luciola Italica luciferase (C6Luc) cells in Wistar rats.
The naïve C6 cells were genetically modified using lentiviral vectors to introduce the GFPLuc gene into the genome of cells. These cells and the C6 cell line, when orthotopically
implanted into the brain of Wistar rats, closely mimics the diffuse growth development of
human GBM and shares several histopathological and genetic markers. The motivation
behind this thesis was to characterize longitudinal C6Luc tumour growth using both BLI
and mpMRI. Although previous studies have reported the use of BLI in monitoring GBM
development (85) and response to therapy (91), no study, to date, has applied both BLI and
mpMRI to characterize the natural progression of C6Luc in an orthotopic rat model. This
thesis aims to characterize the natural progression of orthotopic GBM in a rat model using
both BLI and mpMRI. Current literature does not provide information on how these two
metrics, cellular viability and volumetric tumour metrics, are related and how they describe
the progression of GBM in a rat. I hypothesized that measurements of tumour cellular
viability are required to better understand tumour biology and behavior, and that tumour
cell viability would increase proportionally with measures of tumour volume determined
with mpMRI.
In chapter 2, the multimodality imaging framework of BLI and mpMRI was applied to
longitudinally imaging orthotopic C6Luc tumours in Wistar rats. Despite the initial
hypothesis, the results suggested that the opposite was true. BLI measurements of tumour
cell viability did not increase proportional to tumour burden determined by mpMRI.
Chapter 2 will offer an in-depth discussion and analysis of the possible factors contributing
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to this discordance between two separate measurements of tumour burden and I present
three potential hypotheses to explain the disproportionate changes in BLI and mpMRI
measurements of tumour burden. We also present 2 lines of evidence supporting the
hypothesis that the discordance between BLI and mpMRI measures are due in part to an
increase in necrosis (i.e., decreased tumour cell viability). First, fully co-registered ADC
maps to post-Gd T1-weighted MR images provide evidence that there is a decrease in tissue
cellularity within regions of non-contrast enhancement (i.e., less perfused). In addition,
fully co-registered whole brain histology offers qualitative evidence that necrosis is the
likely cause of proportional changes in BLI and mpMRI measurements.
Chapter 3 summarizes, concludes, and highlights the findings in chapter 2, which provided
evidence to the usefulness of combining both BLI and mpMRI to characterize the
progression of orthotopic C6 GBM tumours. The use of BLI provides a direct measure of
relative tumour cell viability, a metric unobtainable in mpMRI, but lacks the anatomical
and functional information obtainable with mpMRI. The complementary nature of these
two imaging modalities will provide a better understanding of GBM progression in an
orthotopic C6 rat model. Future directions for this research and suggestions for
improvement of our methods are also provided in this chapter.
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Chapter 2

2

Multiparametric Magnetic Resonance Imaging and
Bioluminescence Imaging Characterization of an
Orthotopic Rat Model of Glioblastoma

2.1 Introduction
Glioma is the most common malignant form of primary brain tumour with the highest
mortality rate (1). Grade IV glioblastoma multiforme (GBM) is the most aggressive,
invasive and lethal form of glioma and accounts for approximately 50% of all glioma cases
(2-4). GBM is considered incurable and patient survival after diagnosis is approximately
15-18 months despite aggressive treatment paradigms such as combined surgical resection
(5), radiotherapy, and temozolomide chemotherapy (6, 7). These highly-aggressive
malignancies have a tendency to undergo necrosis (8), are highly invasive and proliferative
(9, 10), have robust angiogenesis, and are resistant to apoptosis (11, 12). The combination
of these factors contribute to therapeutic resistance and nearly 100% recurrence rates. To
improve our understanding of the progression of this devastating disease and for enhanced
evaluation of new treatment regimens, novel complementary methods for non-invasive
assessment of GBM tumours in both preclinical GBM models and GBM patients are
needed.
Preclinical mouse and rat models of glioma have been invaluable for understanding GBM
progression, evaluating novel therapeutic strategies, and for developing new imaging
techniques for better tumour characterization (13-15). In particular, the orthotopic C6 rat
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model has provided a great deal of insight into biological mechanisms and progression of
GBM (9, 14, 16-18). The C6 cell line was first developed by the Sweet laboratory in the
1960s by repeated intravenous administration of the carcinogenic alkylating agent, Nmethyl-N-nitrosourea to outbred adult Wistar rats (19, 20). C6 tumours share several
specific tumour markers found in human GBM such as increased Ras pathway activity,
increased platelet-derived growth factor-beta, insulin-like growth factor 1, epidermal
growth factor receptor, human epidermal growth factor receptor 3 and glial fibrillary acidic
protein expression (14). C6 tumours also share histopathological features found in human
GBM such as a diffuse infiltrative pattern (9). Due to these favourable characteristics, C6
tumour-bearing rats have been used to evaluate therapeutic efficacy of various treatment
regimens such as chemotherapy (16), radiotherapy (17), and cytotoxic gene therapy (18).
To facilitate improved evaluation of treatments and a better understanding of tumours in
the C6 model, numerous groups have utilized clinically-relevant imaging tools such as
positron emission tomography (PET)(21), computed tomography (CT)(22), and magnetic
resonance imaging (MRI)(23). MRI has become the standard of care for the detection,
staging, and assessment of treatment response in glioma patients (24). Benefits of MRI are
the ability to collect high resolution images with excellent soft tissue contrast without the
use of ionizing radiation, allowing changes in tumour morphology and function to be
monitored over time. Various MR contrast mechanisms are available, which can accentuate
different tumour features allowing better identification of tumour mass from other
confounding features such as edema or hemorrhage. Multiparametric MRI (mpMRI)
involves collection of a suite of MRI images with different contrast mechanisms, providing
both functional and anatomical information about tumours such as total tumour volume,
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contrast-enhanced tumour volume, ADC, and tumour perfusion (25). Multiparametric MRI
has previously been applied to the orthotopic C6 rat model (23, 26-28). For instance, Liao
et al., working with the C6 rat model used MRI to gather information about tumour volume
and location, blood brain barrier integrity, and edema (29). However, MRI lacks a sensitive
biomarker to measure tumour cellular viability and any changes in tumour size are slow to
detect in MRI because morphological changes are slow to occur.
In addition to clinical imaging tools, preclinical imaging tools can provide additional
valuable information on tumour biology. Bioluminescence imaging (BLI) is a molecular
imaging modality that is dependent on engineering cells to express a luciferase reporter
gene (e.g., red-shifted Luciola Italica luciferase (Luc)) prior to implantation into animals.
Thereafter, one can image the light produced by these engineered cells with a cooled
charge-coupled device camera following systemic administration of the appropriate
luciferin substrate (e.g., D-luciferin)(30). The main advantage of BLI is the ability to
sensitively track the relative viability of cells over time due to the requirement of cells to
transcribe the reporter, as well as the use of ATP as a co-factor for light production. As
observed in other cancer models (31, 32), changes in BLI measures of cellular viability
may or may not change proportionally to MRI measures of total tumour burden, meaning
BLI provides complementary information to MRI for tracking tumour progression. BLI
has been previously applied to the C6 model. Xi et al. used BLI to track treatment response
of vincristine administration in Fischer 344 rats carrying luciferase-expressing C6 tumours
in the brainstem (33). Hwang et al. applied BLI to monitor tumour growth in mice bearing
luciferase-expressing C6 cells in the hind limb (34). Thus, both mpMRI and BLI have
separately been applied to the C6 model (33, 35), and this imaging study was the first to
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compare longitudinal BLI and mpMRI data in untreated orthotopic C6 rat glioma with
histology at end-point. Current literature provides little information to how BLI and
mpMRI metrics of tumour burden relate in the C6 GBM rat model. Although these two
metrics may be understood separately, it is important to characterize the two metrics in one
study to fully understand the nature of tumour progression. We hope to be able to show the
usefulness of BLI as a measurement of tumour viability, but to also show that a
multimodality imaging framework is required to fully understand tumour biology. The goal
of this chapter was to apply a multimodality imaging framework to the orthotopic C6Luc
rat model to characterize the natural progression of GBM with both BLI and mpMRI. We
hypothesized that metrics of tumour viability in BLI would not only increase proportionally
with metrics of tumour volume in mpMRI, but would also provide complementary
information required to better understand the tumour biology during progression. We found
that the combination of these imaging methods provided new insights into GBM
development in this model, and will be useful for more precise future preclinical evaluation
of the effectiveness of new treatment strategies to help combat this disease compared to
utilizing a single imaging modality.

2.2 Methods and Materials
2.2.1

Cells

C6 rat glioma cells (CCL-107, American Type Culture Collection, Manassas, VA) were
grown in Ham’s F-12K (Kaighn’s) medium (Invitrogen, Carlsbad, CA, USA) containing
2.5% fetal bovine serum (FBS), 15% horse serum and 1% penicillin-streptomycin. All cells
were grown at 37°C in a 5% CO2 incubator. Cells were regularly confirmed to be
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mycoplasma-negative using the MycoAlert Mycoplasma Detection Kit (Lonza, Basel,
Switzerland).

2.2.2

Lentiviral Transduction

Self-inactivating lentiviral particles co-expressing red-shifted Luciola Italica luciferase
(Luc) and green fluorescence protein (GFP) under the control of the Ubiquitin C promoter
were used (RediFect; PerkinElmer, Waltham, Massachusetts, USA). For efficient coexpression Luc and GFP are separated by a T2A “self-cleaving” linker peptide in this
vector. C6 glioma cells were transduced for 24 hours at a viral multiplicity of infection
(MOI) of 50 using polybrene (8 µg/mL). Following transduction, engineered C6 cells that
had the highest co-expression of GFP and Luc (C6Luc) were isolated by fluorescenceactivated cell sorting (FACS) using a BD FACSAria™ III sorter (BD Biosciences, Franklin
Lakes, New Jersey, USA). During the first sort, cells were gated to obtain the brightest
GFP expressing cells (4.52% of all cells) and the cells were propagated and expanded
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(Figure 2-1C). During the second sort, cells with the top 10% fluorescence intensity were
selected for and expanded, as shown in Figures 2-1C & D.

Figure 2-1. Lentiviral Engineering of C6 Glioma Cells with Reporter Genes.
A) Expression cassette of Luc-GFP lentiviral vectors. UbC = Ubiquitin C promoter; GFP
= green fluorescent protein; Luc = red-shifted Luciola Italica luciferase; T2A = selfcleaving linker peptide. B) left: bright field image of C6Luc cells post-sort in vitro, right:
fluorescence image of GFP expression in vitro. Scale bar = 100 µm. C) FACS of control
(naïve C6; gray) and C6Luc (green) cells post-transduction. Cells were gated to obtain the
brightest GFP expressing cells; 4.52% of all glioma cells. D) Second FACS to select the
top 10% of GFP expressing cells after propagation of highest GFP expressing cells from
the initial FACS. E) Immediately after the second FACS (D), a FACS analysis was
performed to evaluate GFP expression in the final population (100% of cells expressed
GFP).
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2.2.3
2.2.3.1

In Vitro Cell Analysis
Doubling Rate

C6 and C6Luc cells were seeded into individual wells of a six-well plate (2×103 cells/well;
n = 3 per cell type). An additional three six-well plates were seeded with C6Luc cells
incubated with 150 µg/mL of D-luciferin (C6Luc150). The total cell number in each well
was determined using a haemocytometer, every 24 hours up to 144 hours. The doubling
rates of the cell lines were determined using the model, 𝑦 = 𝑎×2𝑡/𝑏 . Here y is the cell
count, a is the number of cells in the initial seed, t is the amount of time elapsed in hours,
and b is the doubling time of the cells in hours. A MATLAB script employing the nonlinear least squares Trust-Region algorithm from the Curve Fitting Toolbox (MATLAB
2016b, The MathWorks Inc., Natick, MA, USA 2000) was used to determine parameters
a and b.

2.2.3.2

Radiance vs Cell Number

Known numbers of C6Luc cells (1×106, 5×105, 2.5×105, 1.25×105, 6.25×104 and 3.13×104)
were seeded into individual wells and incubated for 24 hours. D-luciferin (150 µg/mL) was
added to each well, and plates were imaged five minutes later with an IVIS Lumina XRMS
In Vivo Imaging System (PerkinElmer, MA, USA). Images were analyzed using Living
Image Software (IVIS Imaging Systems, PerkinElmer, MA, USA) to obtain the average
radiance (photons/sec/cm2/steradian) per well.
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2.2.4

Orthotopic C6 Glioma Rat Model

All animal procedures were performed in accordance with relevant guidelines and
regulations stipulated by an animal use protocol approved by the University Council on
Animal Care, Animal Use Subcommittee at Western University (Animal Use Protocol:
2010-040). Male Wistar rats (n = 11; Charles River Laboratories) aged 4-6 weeks and
weighing 200-225 g were used. Rats were anesthetized with 5% isofluorane, maintained at
2% isofluorane (1 L/min oxygen) and placed into a stereotactic frame for cell implantation
(Stoelting Co., IL, USA). Fur on the superior side of the head was removed to expose the
skin prior to incision to mark the bregma, which is the area of the skull where the sagittal
and coronal sutures joining the parietal and frontal bones meet. A burr hole was drilled 1mm anterior and 3-mm right-lateral to the bregma. A micro-syringe (Hamilton 1700 series)
containing 106 C6Luc cells suspended in 10 μL of Hank’s Buffered Salt Solution (HBSS)
at 37°C was advanced to a depth of 4 mm in the brain. The cells were injected at a rate of
3 µL/min. Bone wax was used to fill the burr hole to prevent cell suspension reflux. The
incision was sutured and 1 mL of Meloxicam (5 mg/mL; Metacam, Boehringer Ingelheim
Vetmedica, Ingelheim, Germany), a nonsteroidal anti-inflammatory drug, was
administered by a subcutaneous injection. Each animal was imaged with BLI and mpMRI
on days 4, 8, 11, 15 and 18 post-surgery. Prior to each imaging session, all animals had a
tail vein catheter inserted and secured after being anesthetized with isofluorane.

2.2.5

Bioluminescence Imaging (BLI)

Anesthetized rats were given an intraperitoneal injection of D-Luciferin (150 mg/kg;
PerkinElmer, Massachusetts, USA) and imaged on an IVIS Lumina XRMS In Vivo

47

Imaging System (PerkinElmer, Massachusetts, USA). To avoid imaging through the burr
hole, animals were placed on their left side (tumour side closest to the camera) and images
were collected for up to 30 minutes post-injection with the following parameters; exposure
time = 1 min, binning factor = 8, f -number = 1, field of view = 12.5 cm.

2.2.6

Multiparametric Magnetic Resonance Imaging (mpMRI)

Animals were imaged on a 3 T MRI scanner (Discovery MR750 3.0 T, General Electric
Healthcare, Illinois, USA). The heads of anesthetized rats were placed inside an eight-rung,
33-mm-inside-diameter bird cage radiofrequency (RF) coil (Morris Instruments Inc.,
Ontario, Canada), which was located within a custom-built insertable gradient coil (36).
Each MRI session consisted of T2-weighted imaging, diffusion tensor imaging (DTI), and
pre- and post-contrast enhanced (CE) T1-weighted imaging using gadolinium-DTPA (0.5
mmol/kg; Magnevist, Bayer, Leverkusen, Germany). 3D T2-weighted images were
collected using a 3D fast spin-echo (CUBE, General Electric Healthcare, Illinois, USA)
sequence with the following parameters: Repetition time (TR) = 4000 ms, echo time (TE)
= 62 ms, echo train length (ETL) = 160, field of view (FOV) = 60×30×30 mm, acquisition
matrix = 128×128×100, slice thickness = 0.6 mm, bandwidth = 62.5 kHz, and number of
averages (NEX) = 9. DTI data were obtained using a 2D spin-echo single-slice echo-planar
imaging sequence with the following parameters: TR = 6000 ms, TE = 71.1 ms, FOV =
60×60 mm, acquisition matrix = 120×120, 130 coronal slices, slice thickness = 3 mm,
bandwidth = 166.7 kHz, NEX = 1, b-value = 1000 s/mm2. Pre-CE (n = 5) and post-CE T1weighted images were obtained using a 3D ultrafast gradient-recalled echo sequence for
brain volume imaging (Fast GRE BRAVO, General Electric Healthcare, Illinois, USA)
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with the following parameters: TR = 6.9 ms, TE = 2.9 ms, preparation time = 450 ms, FOV
= 60×30×30 mm, acquisition matrix = 120×120×60, slice thickness = 0.5 mm, bandwidth
= 62.50 kHz, NEX = 9, flip angle = 25°. Post-CE T1-weighted images were obtained 4
minutes after Gd-DTPA injection.

2.2.7

Image Analysis

For BLI, average radiance (photons/second/cm2/steradian) was measured using Living
Image software by drawing a region-of-interest (ROI) over the head. For MRI, apparent
diffusion coefficients (ADC) were calculated using a vendor-provided software analysis
package for brain diffusion tensor imaging (Functool, General Electric Healthcare, Illinois,
USA). Tumour volume measurements were obtained from T2-weighted and Post-Gd T1weighted images using ITK-SNAP, a freeware image analysis tool (www.itksnap.org).
Tumour boundaries, chosen based on post-contrast-enhanced (CE) T1-weighted images,
were manually contoured in ITK-SNAP and tumour volumes were calculated. If noncontrast enhanced (NCE) regions were present within tumours, separate ROIs were drawn
to measure CE and NCE tumour volumes. Histology images were co-registered to post-Gd
T1-weighted MR images using 3D Slicer (Surgical Planning Laboratory, Harvard Medical
School, Boston, Massachusetts) with a non-rigid, interactive, thin-plate spline extension by
Gibson (37). Fiducial markers for the registration were placed within 3D Slicer on
histological images and post-Gd T1-weighted MR images on identical morphological
landmarks in the brain of the rat.

49

2.2.8

End-Point Histology

At end-point (18 days post-cell injection), animals were anesthetized with isofluorane and
intravenously injected with pimonidazole (60 mg/kg; HypoxyProbe™-1; Hypoxyprobe
Inc., Massachusetts, USA). After 30 minutes, animals were euthanized with an overdose
of isofluorane followed by a 1-mL tail-vein injection of 1-M potassium chloride to ensure
cardiac arrest. Each rat was pressure perfused with 4% paraformaldehyde (PFA) in
phosphate buffer solution through the left ventricle. Following perfusion, the brain was
excised and stored at 4°C in 4% PFA for an additional 24 hours. Brains were placed in
solutions of progressively increasing glucose concentration (10%, 20% and 30% w/v) for
1 hour, 1 hour and 24 hours, respectively. Brains were then embedded in optimal cutting
temperature compound and frozen at -80°C with a mixture of dry ice and methanol. Tenmicron sections were obtained on a microtome-cryostat (Leica CM1860, Wetzlar,
Germany) and stained for the following: hematoxylin and eosin (H&E); 4',6-diamidino-2phenylindole (DAPI); and hypoxia using the HypoxyProbe™-1 kit (Hypoxyprobe Inc.,
Massachusetts, USA). All whole brain histological images were obtained on an upright
Zeiss Axio Imager Z1 (Carl Zeiss CG, Oberkochen, Germany), which included both bright
field and fluorescence images. H&E, DAPI, green fluorescent protein (GFP), and hypoxia
images were obtained.

2.2.9

Statistics

Statistical analyses were performed with the aid of a statistical analysis software known as
GraphPad Prism v7 (GraphPad Software, Inc., California, USA). A one-way ANOVA and
Tukey’s post hoc test was performed for the cell doubling time. For most imaging
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measurements over time, a one-way repeated measures ANOVA and Tukey’s post hoc test
was performed. A two-way repeated measures ANOVA and Sidak’s post hoc test was
performed to compare the ADC values between the CE and NCE groups over days 15 and
18. Pearson product-moment correlation and linear regression analyses were performed to
identify any trends between any two given imaging measures. All statistical analyses were
performed using a statistical value of P = 0.05.

2.3 Results
In vitro experiments were performed to evaluate the relationship between BLI signal
intensity and cell number (Fig 2-2A/B), as well as the growth rates of C6Luc and naïve C6
cells (Fig 2-2C). A strong positive correlation was found between cell number and BLI
signal (Fig 2-2A/B; R2 = 0.985, P < 0.05; n = 3 for each group). No significant difference
was detected between the doubling rates of C6 cells (11.9 ± 1.7 h), C6Luc cells (12.4 ± 1.7
h), and C6Luc cells incubated with D-Luc (10.3 ± 1.0 h)(P = 0.801).
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Figure 2-2. In vitro analysis of luciferase expression versus cell numbers, doubling
rate, and luciferase activity over passage number.
A) Bioluminescence image overlaid on a bright field image of a six-well plate (n = 3)
containing varying numbers of C6Luc cells, as shown. B) Image analysis showed a strong
correlation between average radiance and the number of cells per well (R2 = 0.985, P <
0.05). C) Doubling rates for non-transduced C6 glioma cells (n = 6), transduced C6Luc
cells (n = 6), and C6Luc cells incubated with 150 µg/mL of D-Luciferin (n = 6). No
significant differences in doubling rates were noted.
A total of 11 Wistar rats were monitored with longitudinal BLI and mpMRI on days 4, 8,
11, 15 and 18 following intracranial implantation of C6Luc cells. During longitudinal
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imaging, one rat was sacrificed prior to end-point due to a rapidly increasing tumour burden
and deterioration of health; data from this animal was omitted. BLI images of a gliomabearing rat are shown in Figure 2-3A. No significant changes in BLI signal were detectable
across time (Figure 2-3B; P > 0.05). There were large variations in the magnitude of BLI
signal across time when considering individual animals. Within 7 of the 11 of the rats, the
average radiance peaked on or near day 11 (group average: 5.2 ± 5.6  105 p/s/cm2/sr) and
dropped two-fold by day 15 (group average: 2.1 ± 2.3  105 p/s/cm2/sr) and nearly threefold by day 18 (Fig 2-3C; pattern 1; group average: 1.9 ± 2.4  105 p/s/cm2/sr). In contrast,
for two rats, BLI signal increased gradually and plateaued around day 15 and 18 (Fig 23C; pattern 2); and for the final two animals, BLI signal slowly decreased after day 4 (Fig
2-3C; pattern 3).
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Figure 2-3. BLI of C6Luc orthotopic tumour growth in Wistar rats.
A) Bioluminescence images collected from days 4 to days 18 post-cell implantation. BLI
images are overlaid on bright field images of a rat lying on its left side (tumour implanted
in right side of brain). Left: Representative images of a rat where BLI signal increased from
day 4 to day 11 followed by a drop in BLI signal on days 15 and 18. Right: Representative
images of a rat where BLI signal steadily increased and plateaued. B) Due to large intersubject variability, analysis of brain BLI signal (average radiance) revealed no significant
changes with respect to time (P > 0.05). C) The three BLI patterns observed between
individual animals. Data are presented as mean ± SD.
We noted qualitative morphological differences in brain and tumour MR features across
animals. Nine rats displayed tissue damage from the needle tract during injection until endpoint, and seven rodents displayed defined tumour boundaries. One rat displayed evidence
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of a hemorrhage on day 11 based on T2-weighted MRI but recovered by day 18 (not shown
in this thesis). Tumour volumes were measured on both T2-weighted and post-CE T1weighted MR images (Fig 2-4A). Based on T2-weighted MRI, eight rodents had tumours
that monotonically increased to an average volume of 275 ± 175 mm3 by day 18. Two
rodents displayed a decrease in tumour volume from day 15 to day 18, and 2 rodents had
tumour volumes that decreased continually after day 11. Total tumour volume based on T2weighted MRI significantly increased from 11 ± 9 mm3 on day 4 to 215 ± 126 mm3 on day
15 (Fig 2-4B; P < 0.05). No significant change in tumour volume were observed from day
15 to day 18 (P = 0.230).
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Figure 2-4. Representative longitudinal post-Gd T1- and T2-weighted MRI of C6Luc
tumour growth.
A) T2-weighted images (left) and post-Gd T1-weighted (right) MRI of a representative
animal brain showing continued tumour growth over time. Tumours were manually
contoured (red) and total T2 (B) and T1 (C) tumour volume over time was determined (n =
11 rats). The letters, a, b, c and d, denote significant differences across time points (P <
0.05). Data are presented as mean ± SD.
Similar to T2-weighted images, five rodents displayed increasing post-CE T1-weighted
tumour volume from 23.3 ± 9.80 mm3 on day 4 to 235 ± 168 mm3 on day 18. Three rodents
peaked in tumour volume on day 15 and decreased on day 18, two rodents had decreasing
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tumour volume past day 11 and one rodent had a decrease in tumour volume on day 15,
but rapidly increased by day 18. Post-CE T1-weighted tumour volumes exhibited a
statistically significant increase from 23 ± 10 mm3 on day 4 to 145 ± 87 mm3 on day 11
(Fig 2-4C; n = 11; P < 0.05). No significant changes in post-CE T1-weighted tumour
volumes were observed between day 11 and 18 (P = 0.230).
Post-CE T1- and T2-weighted tumour volumes had a strong positive correlation (Fig 2-5A;
R2 = 0.884, P < 0.05). In contrast, when all five longitudinal imaging time points were
considered, T2-weighted tumour volumes were not significantly correlated to BLI signal
(Fig 2-5B; R2 = 0.027, P = 0.226) and post-CE T1-weighted tumour volumes were poorly
correlated to BLI signal (Fig 2-5C; R2 = 0.074, P < 0.05). To further investigate the
relationship between total tumour volume and BLI signal, T1- and T2-weighted tumour
volume data from days 4 to 11 were compared to BLI signal on those days. Both T1 and T2
tumour volumes were moderately correlated to BLI signal when considering only days 4
to 11 (Fig 2-5D; R2 = 0.305, P < 0.05; Fig 2-5E; R2 = 0.237, P < 0.05), suggesting a
relationship in tumour volume and BLI signal during early, but not late, tumour progression
(i.e., beyond day 11).
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Figure 2-5. Correlational plots of total T2 and post-Gd T1 tumour volume to BLI
signal.
A) Post-Gd T1-weighted tumour volume was strongly correlated to T2-weighted tumour
volume. B) T2 tumour volume was not correlated to BLI signal across all imaging days (4
to 18). C) T1 tumour volume was poorly correlated to BLI signal across all imaging days
(4 to 18). D) T1 tumour volume was moderately correlated to BLI for data from days 4 to
11 only. E) T2 tumour volume was moderately correlated to BLI for data from days 4 to 11
only. Day 15 and 18 were excluded due to the formation of a NCE region. The line of best
fit and the 95% confidence interval was plotted for each graph.
Beyond day 11, we noted in post-CE T1-weighted MR images that there were foci within
some tumours, primarily within the core, which did not appear to enhance. Therefore, we
separately measured the contrast enhanced (CE) and non-contrast-enhanced (NCE) tumour
volumes to evaluate whether these measurements correlated with BLI signal beyond day
11. One rodent displayed hypo-intense regions within the tumour in post-CE T1-weighted
MRI on day 8 but it was not possible to differentiate between tissue damage due to the
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needle tract or lack of contrast agent; therefore, this animal was excluded from data
analyses. Two of the seven rodents did not have a NCE region on day 11 and it was likely
that these NCE regions on day 11 were due to tissue damage from the surgery needle,
therefore this day was excluded from analyses. It is impossible to perform a repeated
measures ANOVA without extrapolating the data for day 11. In addition, these NCE
regions were superficial and was associated with the tissue damage from stereotactic
surgery. Seven of the 11 rodents displayed a NCE region surrounded by a CE region within
the tumour on days 15 and 18, and a representative rodent is shown in Figure 2-6A. CE
tumour volume significantly increased from 23 ± 10 mm3 on day 4 to 143 ± 85 mm3 on
day 11 (Fig 2-6B; P < 0.05). No significant changes in CE tumour volume were observed
from days 11 to 18 (P > 0.05). NCE tumour volume was not significantly different between
days 15 and 18 (Fig 2-6C; P = 0.119). The relationship between CE tumour volume and
BLI signal was examined to determine if perfusion solely accounted for the lack of
correlation between total tumour volume and BLI signal; however, CE tumour volume was
poorly correlated to BLI signal (Fig 2-6D; R2 = 0.088, P < 0.05).
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Figure 2-6. Longitudinal post-Gd T1-weighted MRI with CE and NCE regions
differentiated and examined for correlation.
A) Representative post-Gd T1-weighted MR images of a representative rat with CE and
NCE regions contoured in red and blue, respectively. B) CE tumour volume significantly
increased over time, whereas NCE tumour volume (C) did not significantly change from
day 15 and 18. D) T1 CE tumour volume was slightly more correlated to BLI signal when
compared to T1 tumour volume, but still had a very poor correlation. The line of best fit
and the 95% confidence interval was plotted. Significantly different groups are denoted by
the letters, a, b, and c. All data are shown as mean ± SD.
To evaluate water diffusivity within tumours as a measure of cellularity, we performed DTI
of rats over time (Fig 2-7A). An ADC map and matched post-CE T1-weighted MR images
of a representative animal, with CE and NCE regions contoured, are shown in Figure 2-
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7A. On day 4, there was large variability in ADC values, which was presumably due to
tissue damage from the needle tract during stereotactic surgery. Whole tumour ADC values
significantly increased from days 8 and 11 to day 18 (Fig 2-7B; P < 0.05). Of the 7 rodents
that displayed NCE regions within tumours at day 15 and 18, the ADC values within these
NCE regions were significantly higher than in CE regions (Fig 2-7C; P < 0.05).

Figure 2-7. Longitudinal apparent diffusion coefficient (ADC) maps and post-Gd T1weighted MRI with their respective plots.
A) ADC maps (left) overlaid on T1-weighted MR images with CE (red) and NCE (blue)
ROIs contoured (right). B) ADC values over the whole contoured (red) tumour plotted
against time. Whole-tumour ADC values significantly increased on day 18 when compared
to days 8 and 11. C) ADC values within NCE or CE regions plotted with respect to time.
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ADC values within NCE regions were significantly increased on both day 15 and 18 when
compared to ADC values in CE regions. * denotes significant differences at P < 0.05. All
data are shown as mean ± SD.
At end-point, qualitative assessment of co-registered H&E microscopy images and postgd T1-weighted MRI demonstrated that large regions of tissue lacking nuclei or
cytoplasmic proteins within tumour tissue (Fig 2-8; H&E) corresponded to areas of noncontrast enhancement (Fig 2-8; Post-Gd T1). Co-registered DAPI images (Fig 2-8; DAPI)
show nuclei staining, which corresponds to the presence of nuclei from H&E staining.
Results from DAPI staining are similar to H&E; there are many nuclei in peripheral tumour
tissue, and a lack of nuclei near the centre of the tumour mass. GFP is co-expressed with
Luc, therefore GFP microscopy (Fig 2-8; GFP) displayed cells (i.e. C6Luc) that were
actively transcribing and translating the GFP and Luc genes at end-point. GFP is detectable
within regions of viable tumour tissue (which correspond to areas where tumour nuclei are
present), but undetectable in regions that lack nuclei. Very low levels of GFP could be
detected in Fig 8, rows #3 and #4, despite the presence of intact tumour tissue. Hypoxia
staining (Fig 2-8; Hypoxia) demonstrated regional hypoxia within the tumour. There are
few regions of hypoxia, predominately within the tumour and adjacent to regions lacking
nuclei within the tumour. DAPI, GFP and hypoxia were overlaid (Fig 2-8; DAPI GFP
Hypoxia) to demonstrate areas of GFP were coincidental with DAPI and to provide contrast
to hypoxia staining to identify morphological features. Co-registered ADC maps (Fig 2-8;
ADC) show regions of increased ADC values which correspond to NCE regions on postGd T1-weighted MR images and to the extracellular matrix and empty regions on histology.
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Figure 2-8. Fully co-registered whole brain histology, which includes H&E, DAPI,
GFP and hypoxia, to post-Gd T1-weighted MR images with the respective coregistered ADC maps of four representative animals.
A) Post-Gd T1-weighted MRI shows NCE and CE regions, and was the reference image
for non-rigid transformation. Hematoxylin stains for positively charged structures (i.e.
nuclei). Eosin stains for negatively charged structures that can be found within the cell (i.e.
compounds and proteins commonly found in the cytoplasm). DAPI is a fluorescent dye
that binds to A-T rich regions in DNA (i.e. nuclei). GFP is co-expressed with Luc, therefore
only active, live cells can transcribe the gene and express the protein. Hypoxyprobe™
(pimonidazole) stains for hypoxic regions, where the pimonidazole binds to thiolcontaining proteins in hypoxic cells. DAPI, GFP and hypoxia images were overlaid.
Respective ADC maps of each animal demonstrated an increased in ADC values within
NCE regions.
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2.4 Discussion
In this study, we present the first use of combined BLI and mpMRI to quantitatively
characterize orthotopic C6 tumour growth in rats, a well-documented model of glioma (14,
15, 38). The combination of these two imaging modalities allowed complementary
assessment of multiple tumour growth characteristics, including total tumour volume, CE
and NCE tumour volume, ADC measures for whole tumour, CE and NCE regions, as well
as relative cellular viability using BLI. Conventional MRI, which includes post-CE T1- and
T2-weighted MRI, is an excellent non-invasive imaging tool to longitudinally assess
morphological changes in the brain. However, conventional MRI is mainly limited to
morphological and functional information, and, unlike BLI, does not directly measure the
viability of cells over time in rat models. An added benefit of using BLI is that it can
sensitively detect changes in tumour viability prior to any changes in tumour burden
because morphological changes are slow to occur when compared to molecular changes.
Unfortunately, BLI provides little anatomical information and spatial information is
degraded by light scatter through tissue and the skull. Thus, a combination of both mpMRI
and BLI may overcome the limitations of each individual modality and provide
morphological, functional and molecular information about tumour growth in this rat
model.
Our imaging results indicated that MR measurements of tumour volume did not correlate
with BLI signal beyond day 11 (Fig 2-5). This highlights the complementary nature of our
imaging approach as new information is provided with BLI that is not attainable with
conventional MRI measures of tumour burden. Previous studies have reported a linear
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relationship between tumour volume and BLI signal for glioma models (31, 39-42).
However, other studies have reported similar findings as this study; observing a lack of a
relationship between tumour volume and BLI signal, particularly at later time points when
tumour cores can become ill-perfused and/or necrotic. Jost et al. reported a small subset of
animals (n = 2) demonstrating decreased BLI signal despite increasing tumour volume and
attributed it to hemorrhage and necrosis (31). Likewise, Rehemtulla et al. support these
findings, and concluded that BLI signal was less correlated to MRI measurements with
necrotic tumours in the case of treated tumours or large untreated tumours (32).
In support of the evidence presented by Jost et al. (31) and Rehemtulla et al. (32), regions
that did not enhance on post-Gd T1-weighted MRI (NCE regions) became apparent beyond
day 11, the time point after which BLI signal decreased in the majority of animals, and
these corresponded to regions of significantly increased ADC values from diffusion
weighted imaging (DWI). DWI is a functional MRI technique that is sensitive to small
changes within tissue and has become a useful tool to characterize brain tissue cellularity.
Sugahara et al. has previously described the inverse relationship between tumour
cellularity and apparent diffusion coefficient (ADC) values (43). An increase in tissue
cellularity would restrict the movement or diffusion of water molecules and vice versa.
Previous studies have described this relationship between cellularity and tumour necrosis
(44-46). Tumour cellularity assessed by ADC measurements decreased significantly over
time (Fig 2-7B). Tumour cellularity has been reported to decrease in the event of edema,
hemorrhage, and necrosis among other factors (23, 26, 47). Edema and hemorrhage has
been ruled out as potential causes of decreased tumour cellularity because edema appears
as hyper-intense and hemorrhage appears as hypo-intense signals in T2-weighted MRI, both
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of which were not present in this study when T2-weighted MR images were examined.
NCE regions within the tumour had significantly increased ADC values when compared
to CE regions on days 15 and 18 (Fig 2-7C). Moreover, our co-registered end-point whole
brain immunohistochemistry provided qualitative evidence to further strengthen this
finding. Microscopy analysis of H&E stained sections allowed specific features to be
differentiated when comparing healthy brain tissue and tumour tissue, such as tumour
tissue pattern, and focal areas of necrosis (48). H&E staining showed regions of necrosis
within the tumour that corresponded to NCE regions and regions of high ADC values (Fig
2-8). In addition, DAPI images demonstrate that there were very few nuclei in regions
identified as necrotic in H&E images, NCE regions and regions of high ADC values. The
C6 tumour cells co-expressed GFP and red-shifted Luciola Italicia luciferase; no GFP
signal was detected within these necrotic regions based on GFP microscopy images. In two
cases, we found very little detectable GFP signal within CE and NCE regions of very large
tumours as seen in rows #3 and #4 in Figure 2-8. Overall, our findings supported previous
findings in literature and the presence of necrosis in the C6 rat model as the main
contributor to the decrease in BLI signal in a majority of the animals,
Brutkiewicz et al. reported similar findings to this study but contributed the discordance of
BLI signal and MRI metrics to the luciferase-luciferin reaction impeding tumour growth
in high luciferase expressing cell lines (49). Contrary to this, our study has demonstrated
in vitro that D-luciferin incubation had no significant effect on growth rate of C6Luc
tumour cells (Fig 2-2C). Zhao et al. had previously described that BLI signal may be
restricted due to limited delivery of BLI substrate to the tumour (50). The lack of Gd-DTPA
uptake and decreased cellularity strongly suggested that these tumours have developed an
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ill-perfused necrotic core, which was not uncommon of GBM as previously described in
literature (51, 52). However, Doblas et al. states that gadolinium is not a specific, direct
measure of angiogenesis nor perfusion, and only reflects an impacted BBB (16). Thus,
having a direct measure of perfusion, such as PWI, would have been a powerful
measurement to rule out limited substrate delivery or limited vascularization.
Khalil et al. has reported that hypoxic regions within the tumour may have a negative
influence on BLI signal due to the inherent requirement of oxygen in the luciferinluciferase reaction (53). We found small regions of hypoxia, which were predominately
adjacent to necrotic regions, present within tumours based on immunohistochemistry (Fig
2-8; #1 and #2). There were two cases were hypoxia was undetectable within both CE and
NCE regions of the tumour despite large tumours with necrosis present (Fig 2-8; #3 and
#4). This qualitative assessment supported previous findings in literature, as hypoxia was
present within the tumour which can limit the luciferase-luciferin chemical reaction.
However, it is unlikely the primary cause of the three-fold decrease in BLI signal due to
the lack of hypoxia staining.
We propose that all these factors (necrosis, hypoxia, and limited substrate delivery) are
contributors to the decreased BLI signal we see in our study at later time points in the
majority of animals. In addition, these three factors are all related. The lack of
vascularization to certain regions of the tumour may limit blood and oxygen delivery
causing these regions to become hypoxic, which would eventually become necrotic, due to
a mismatch of metabolic supply and demand (54, 55). The increased metabolism of tumour
cells (56) which leads to the lack of oxygen and adenosine triphosphate (ATP) creates a
difficult environment for the luciferin-luciferase reaction to go to completion because this
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BLI reaction requires both ATP and oxygen as co-factors. The increased metabolism of
tumour cells, decreased oxygen and ATP availability, limited vascularization within the
tumour limits D-luciferin availability, preventing the luciferase-luciferin pathway from
producing detectable light (50).
As mentioned previously, mpMRI metrics (NCE and high ADC regions) correspond to
areas of necrosis as determined in immunohistochemistry (Fig 2-8). Therefore, it can be
qualitatively concluded that in vivo imaging can accurately recapitulate and provide
information on real morphological changes, evident in post-mortem histology. It can be
inferred that NCE regions on day 11 and 15 are likely signs of early-necrosis. Thus, we can
non-invasively monitor the tumour and identify growth characteristics such as the
formation of necrosis. In further support of this particular inference, functional imaging
provided another metric, cellularity, which can be related to the formation of a necrotic
core. Interestingly, the lack of correlation between mpMRI and BLI measurements
highlighted the importance of having an independent measurement of tumour viability on
a molecular level. We have shown here that BLI provides an important measure
unobtainable in mpMRI, which is cellular viability. We have shown in this study that BLI
signal tended to decrease after day 11, in which areas of NCE or necrosis began to form.
BLI is sensitive to changes in cellular viability and was able to detect a change in viability
before any apparent anatomical changes were present.
Our study highlights the large variability of disease progression across animals in this
model. For instance, two rodents displayed slowly increasing BLI signal over time, with
some decline on day 18 despite increasing tumour volumes. This is important information
and suggests investigating each animal on an individual basis with both BLI and MRI when
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moving forward with the assessment of tumour response to treatment. It would be naïve to
assume that all tumours would respond identically when given the same therapy regimen.
Therefore, the imaging and monitoring of tumour progression and response to treatment
needs to occur on a per animal basis when attempting to deliver or assess the efficacy of a
certain therapeutic plan. Another very important point to mention is the current method to
assess tumour growth characteristics and response to therapy, which is through
morphological changes in tumour volume as seen in mpMRI, has its limitations and may
not be the most sensitive method when used alone in this model. The evaluation of
treatment response based only on tumour volume is inherently flawed, as change is slow
to occur and provides no information on the cellular viability of cancer cells. As this study
has shown, the biology and cellular viability within the tumour was evolving considerably
over time. It is likely that the evaluation of treatment response may be inaccurate in this
model when the only metric for response is tumour volume. This study has highlighted the
complementary value of using both BLI and mpMRI and would prove beneficial to future
studies addressing the evaluation of treatment response in this model.
A limitation of this study is the lack of histological samples obtained at each time point
from different cohorts of animals. Evaluation of this tissue could help confirm the
development of hypoxia, necrosis or lack of perfusion and help explain the imaging
measures obtained with BLI and mpMRI over time. Alternatively, the use of other
molecular imaging tools to identify and measure tumour growth characteristics would
provide a deeper understanding of the various biological mechanisms occurring within the
tumour during progression in this rat model. Some examples are
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F-fluodeoxygluocose

(18F-FDG), which enables metabolic imaging of the tumour through glucose activity, 18F-
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fluoromisonodazole (18F-FMISO), which probes regional hypoxia independent of BBB
disruption and lack of perfusion, and

18

F- galacto-arginine-glycine-aspartic acid (18F-

galacto-RGD), which is a probe for angiogenesis (57). Another imaging modality that
would be useful to improve the ability to describe tumour progression and treatment
response is 1H magnetic resonance spectroscopy (MRS). 1H MRS can measure various
metabolites (e.g. N-acetyl aspartate, choline, and creatine) non-invasively which may aid
in treatment planning and assessment (58). Expanding on MRS, is a novel imaging
technique referred to as HP

13

C MRSI. HP

13

C-pyruvate MRSI is a metabolic imaging

modality that measures the conversation of pyruvate to lactate, which provides information
of metabolism (59). The imaging of metabolism with

18

F-FDG PET or HP

13

C-pyruvate

MRSI provides a method to monitor the biological activity of the tumour, which can be a
useful surrogate measure of treatment response (60, 61). PET-MRI allows for co-registered
PET molecular imaging to MR anatomical images, which opens a window of opportunity
to delineate these various biological features, that include necrosis, hypoxia and
angiogenesis, of GBM in this model.
Knowledge of the tumour microenvironment, its biology and characteristics of natural
progression should be included in interpretation of imaging data used to assess treatment
response. For example, if one was assessing novel therapies in the C6Luc GBM rodent
model using mpMRI and BLI and applied treatment near day 11, one could wrongly
assume that therapy was effective because BLI signal dropped on days 15 and 18, when in
fact, the decrease in BLI signal is often seen in untreated tumours. It will be very interesting
to apply this multimodality imaging framework to evaluate tumour characteristics and
eventually novel therapies in genetically engineered mice (GEM) or patient derived
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xenograft (PDX) glioma models. PDXs are becoming more prevalent in this research field
because they have shown to be highly reflective of human GBM and have been used for
assessing treatment response in mice (62). This assessment of treatment response has been
shown to have strong correlation to predicting clinical response.
In conclusion, this was the first longitudinal study to apply a multimodality imaging
framework, mpMRI and BLI, in an orthotopic C6Luc rodent model to characterize the
natural progression of GBM. This study also applied whole brain histological imaging that
was co-registered to post-Gd T1-weighted MR images to qualitatively assess the correlation
between in vivo imaging metrics to end-point histology. This study highlighted the
importance of having an independent measure of tumour cell viability because assessment
based solely on tumour volumes from MRI was not reliable and did not truly reflect the
nature of GBM in each animal. Changes were slow to occur in MRI, for example, in BLI,
a decrease in tumour viability was detected by day 11 to 15, whereas metrics of tumour
burden in mpMRI suggested a possible decrease in tumour viability (due to the presence
of a necrotic core) by day 15 to 18. In addition, it is difficult to conclude that these NCE
regions correspond to necrotic regions without additional imaging techniques or histology,
as Gd-DTPA is non-specific and reliant on contrast agent delivery. BLI and mpMRI
showed positive correlation on the initial time points, but diverged on days 15 and 18.
Further investigation was warranted and three new main hypotheses were developed, a lack
of substrate delivery or perfusion, the presence of hypoxia and the formation of necrosis
within the tumour. This study has provided evidence for the presence of necrosis, which
contributed to the decrease in BLI signal as qualitatively confirmed through DWI and
histology. This study highlights the difficulties in evaluating treatment response through
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non-invasive imaging in the C6Luc rat model. Future studies should include multimodality
imaging to provide a greater understanding of the disease model and obtain as many
independent metrics of tumour response as practical for accurate assessment. There are
many promising animal models that this imaging framework could be applied to. An indepth imaging analyses of such models during progression may provide new insights to
further improve clinical treatments and outcomes.
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General Discussion and Conclusions

3

Overview

This thesis highlights the usefulness and importance of using multimodality imaging tools
to understand the C6 GBM rat model. Bioluminescence imaging has provided an
independent measure of tumour viability to complement tumour burden measurements
assessed by mpMRI in this model. GBM is an extremely important disease to understand
due to its severity and poor treatment outcomes. The main scientific contributions of this
research will be highlighted and summarized below.

3.1 Summary and Conclusions
In this thesis, naïve parental C6 glioma cells were genetically engineered to stably express
luciferase and the growth of these cells in an orthotopic rat model was characterized using
a multimodality imaging framework that consisted of BLI and mpMRI. One goal of this
thesis was to apply this imaging framework to understand how clinically relevant mpMRI
measurements of tumour burden may be related to an individual measure of tumour
viability assessed with BLI in a longitudinal experiment. A secondary goal of this thesis
was to understand BLI and mpMRI imaging parameters of tumour burden/viability during
natural progression of C6Luc tumours (i.e., no treatment). This will play an important role
in future imaging research involving treated animals because it provides a deeper
understanding of how these imaging metrics assess tumour progression in non-treated
animals, thus allowing us to properly assess the efficacy of the treatment.
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This work began with in vitro demonstration that the genetic modification of C6 glioma
cells and the BLI substrate, D-Luc, had no significant effect on the proliferation rate of the
cells. A linear relationship was observed between cell count and BLI signal intensity in
vitro, thus it is logical to assume that this linear relationship exists for tumour size and BLI
signal intensity in vivo (1). Longitudinal in vivo experiments showed that there were no
significant changes in BLI signal but there were significant increases in post-Gd T1- and T2
MR metrics of tumour volume. The lack of significant changes in BLI could be due in part
to the large variation between animals, as animals with the same tumour implantations can
develop biologically different tumours from one another, as previously reported (1) and as
shown in mpMRI and histology. Correlational analyses showed that post-Gd T1 and T2
offered similar metrics of tumour burden and the results provide evidence that the linear
relationship between BLI signal intensity and mpMRI tumour burden no longer hold true
past day 11 as the two metrics diverge. Upon closer investigation into days 11 to 18, the
formation of NCE regions within the tumour were apparent, which was usually surrounded
by a region of CE tumour. Post-Gd T1-weighted MR images and ADC maps suggest that
NCE regions correspond to regions of decreased cellularity. Histology (H&E, DAPI, GFP
and hypoxia staining), co-registered with the mpMRI data provided evidence that NCE
regions were in fact necrotic, and that among animals, there were varying numbers of viable
tumour cells (as determined by GFP). Hypoxia staining showed small hypoxic regions
within the tumour, providing qualitative evidence that hypoxia may not have been a large
contributing factor to the decrease in BLI signal. These results further suggest that a wide
suite of imaging tools is required to fully understand and characterize GBM progression in
animal models. BLI, mpMRI and immunohistochemistry has provided insight into the
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biology of the tumour and a closer look at biological and morphological features at endpoint.
In summary, this is the first study to date to simultaneously apply BLI and mpMRI to
characterize the natural progression of C6Luc GBM in rodents and to utilize whole brain
histology to qualitatively assess tumour biology and morphology at end-point. The absence
of a direct metric for tumour viability with mpMRI has been addressed by adding BLI.
This study has shown that BLI offers complementary information to MRI that provides
insight into tumour progression, which may have been missed if only the morphological
imaging capabilities of mpMRI were used. Whole brain histology has been used to
qualitatively assess the tumour at end-point, which suggests that NCE regions in post-Gd
T1-weighted MR images and regions of increased ADC values correspond to necrosis.
From these data, it is highly suggestive and probable that the decrease in tumour viability
is a major contributor to the decrease in BLI signal as seen on days 15 and 18.

3.2 Limitations
This section will address some of the major limitations discussed in chapter 2 and in this
thesis as a whole, which will be discussed in further detail below.
As discussed in chapter 2, a major limitation of this study was the lack of quantitative
longitudinal histology. Histology at each time point (days 4, 8, 11 and 15) would have
provided concrete evidence of the various biological and morphological changes occurring
within the tumour rather than inference of the processes based on end-point histology. As
a result, it is more difficult to draw firm conclusions and correlate the various metrics from
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in vivo imaging to the biological and morphological processes apparent in
immunohistochemistry at end-point. Although expensive and time-consuming, the ability
to correlate the amount of necrosis, or hypoxia to in vivo imaging data in a series of
longitudinal measurements across numerous animal cohorts would have been ideal, and
this absence is a notable limitation of this thesis.
Perfusion imaging data would have provided additional evidence for some of the
conclusions and would provide insight into whether the necrotic core was ill-perfused, and
had limited substrate delivery. This should be included in future studies involving
assessment of therapeutic response of solid tumours.
Having a limited sample size (n = 11) made it difficult to conclude any significant trends
between different animal tumour growth patterns. There is concern whether each animal
should be assessed individually or within a group, due to the large biological variation. It
is difficult to draw conclusions regarding observations from individual animals due to the
lack of statistical power, but it is apparent that multiple individuals displayed similar
growth patterns. With a larger cohort size, it may have been possible to propose that there
are patterns of tumour development among animals and subsequently group animals with
similar growth patterns depending on observed BLI trends.
Beyond these study specific limitations, the resolution of our mpMR images could be
improved. Due to limitations associated with some pulse sequence implementations the
maximum performance of the gradient insert was not achieved for this imaging study.
Image voxels were limited to an isotropic resolution of 400 m. Without significant pulse
sequence programming effort, it was not feasible to modify these sequences. The sequences
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used in this experiment were not optimized to be used with the insertable gradient in
research mode. The sequence was hard-coded to prevent a higher resolution.

3.3 Future Directions
The inclusion of multiple modalities into our imaging suite to characterize tumour
progression would be a powerful asset. There are multiple clinically relevant imaging
modalities, such as PET, and novel imaging modalities, such as HP

13

C MRSI, that can

directly probe tumour metabolism and provide information about metabolic pathways
within tumour cells and inform on the tumour microenvironment. These measurements
could be correlated to BLI observations, and would potentially provide a stronger
understanding of tumour biology on a molecular level. In addition to metabolic
information, contrast agents that probe for hypoxia, vascularization or perfusion would
provide a great deal of information regarding the biological microenvironment of the
tumour. The ability to employ various PET tracers, such as FMISO to image hypoxia (2),
or FDG to image tumour metabolism (3), and various MRI techniques, such as perfusion
MRI (4) or HP 13C MRSI to probe metabolism (5), using a hybrid PET/MRI system would
provide a great deal of information in addition to BLI, and would be ideal.
The next steps arising from this research would be to take this multimodality imaging
framework and apply it to the assessment of treatment response in this model. The results
from chapter 2 serve as guide for potential future studies involving novel therapies and the
assessment of its efficacy. Inclusion of an independent measure of tumour viability will
prove to be invaluable for assessment of the efficacy of novel therapies in addition to
morphological changes assessed by MRI, which are slow and lack direct biological and
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molecular information. In addition, other cells within the tumour could experience various
growth rates due to the tumour microenvironment and the heterogeneity of the tumour,
making it difficult to correctly assess treatment response solely on anatomical metrics in
MRI. For example, a researcher using only MRI metrics of tumour burden to evaluate C6
tumour growth and response to treatment may make the mistake of assuming that the whole
tumour mass consists of viable cells (based on T2-weighted images) when this may not be
true based on declining BLI measurements that indicate a shrinking viable tumour volume.
Likewise, it is important to understand the patterns and trends associated with each specific
glioma model and suite of imaging tools. A researcher applying novel therapy on day 11
using both BLI and mpMRI to measure response may make the mistake of misattributing
the true cause of the two-fold decrease in BLI signal from day 11 to 15. This researcher
would likely conclude that the therapy is efficient in treating GBM without a priori
knowledge that progression of this orthotopic C6Luc Wistar rat model often exhibits a
significant reduction in BLI beyond day 11.
Clinically relevant animal models such as patient-derived xenograft (PDX) models (6), are
of a great interest to the type of work described in this thesis. The use of PDX in a rodent
model is extremely useful when considering the evaluation of tumour response to novel
therapies as these models more closely recapitulate the biology of human GBM. The
observed response from treatment in these models would likely better reflect the expected
biological response and efficacy of novel therapies applied in the clinic (7, 8).
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3.4 Significance and Impact
GBM is an incurable disease. Current aggressive therapeutic regimens only slow disease
progression and temporarily prolong the patient’s life. A significant amount of research is
aimed towards developing new treatments (9) and methods to better evaluate existing
treatments (10). This thesis has shown the utility of a multimodality imaging framework
for preclinical GBM research. Multimodality imaging provides important additional
information directly related to tumour biology, which complements tumour morphology.
BLI has been shown to be a useful tool for measuring tumour viability, and provides unique
information in addition to conventional assessment data including tumour volume (T1 and
T2) and tumour cellularity (ADC). Finally, this thesis has provided caution for future
research evaluating novel therapies with imaging without prior comprehensive knowledge
of the typical progression of a particular tumour model.
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